Ajan Reginald | Chief Executive Officer

Ajan Reginald, Chief Executive Officer, Celixir

Ajan Reginald is a co-founder and the Chief Executive Officer of Celixir, which he originally founded under the name Cell Therapy Ltd in 2009 with Nobel Laureate Professor Sir Martin Evans.  Celixir is a British biotechnology company that discovers and develops life-saving and life-altering regenerative medicines for patients with the greatest medical need. Celixir’s unique, world-class technology platform drives in-house discovery and has created a pipeline of 20 tissue-specific regenerative medicines, an unprecedented feat in the field of regenerative medicine. 
Celixir’s pipeline is led by their investigational cardiac regenerative medicine, HeartcelTM which is designed to treat patients with ischaemic heart disease undergoing coronary artery bypass graft. Alongside HeartcelTM, Celixir has late-stage development medicines in orthopaedics and mild to moderate heart failure as well as early phase development medicines in type 1 diabetes and oncology.
Ajan previously served as the Global Head of Emerging Technologies at Roche where he oversaw the identification, acquisition and development of the next generation of breakthrough biopharma technologies and products. He joined Roche as a Business Development Director for Roche Pharma, where he led merger & acquisitions teams and major licensing transactions. He is a former Boston Consulting Group Consultant. Ajan was awarded the Fulbright Scholar, an MBA from Kellogg Business school and studied Experimental Therapeutics (MSC) at the University of Oxford.


Conference Day 1: Thursday 16th May 2019 @ 12:10

Technology and Strategy Roundtables

25 senior level tables hosted by thought leaders on key challenges and opportunities in next-generation therapeutic development. Participants are invited to join the group discussions on a topic of importance to them.· At each roundtable, the moderator will talk for 5 minutes to introduce the topic highlighting particular challenges specific to that area· The table will then move on to discussion for 25 minutes.· There will then be one rotation, giving participants the opportunity to have join two round tables in total(2 x 30-minute rotations and max 15 PAX)

Table 18. Building a diversified portfolio of C> medicines

Conference Day 1: Thursday 16th May 2019 @ 14:35

Panel discussion: Clinical development of next generation cellular therapeutics

  • Clinical updates and discussion
last published: 21/Mar/19 09:25 GMT

back to speakers

There are two parts to the World Advanced Therapies & Regenerative Medicine Congress: a conference and an exhibition featuring solutions for pharma and biotech.

There is a registration fee to attend the conferences. To visit the exhibition is free.


Erica Baeta 
+44 (0)207 092 1152 


Jessica Robinson 
t/ +44 (0)207 092 1150 


Issa Mauthoor 
+44 (0)207 092 1257